Coexistence of COVID-19, Pseudomonas, and thoracic actinomycosis in a cystic bronchiectasis case.
Emine AfsinFurkan KucukHüsna OzcelikMuhammed Yavuz HaktanırPublished in: BMC infectious diseases (2023)
Actinomycosis often leads to cervicofacial infections, but thoracic involvement may also occur. However, the development of empyema is rare. While being followed up with the diagnosis of asthma and bronchiectasis, our case was hospitalized for infected bronchiectasis. As empyema developed in the follow-up, the pleural effusion was drained by tube thoracostomy. Actinomycosis was diagnosed through pleural effusion cytology. Growth of Pseudomonas aeruginosa was observed in sputum culture, and SARS-CoV2 RT-PCR was also positive in nasopharyngeal sampling. Polymicrobial agents can often be detected in actinomycosis. Actinomycosis cases have also been reported in the post-COVID period. Our case is presented since it would be the first in the literature regarding the coexistence of COVID-19, Pseudomonas, and thoracic Actinomycosis (empyema).
Keyphrases
- sars cov
- cystic fibrosis
- pseudomonas aeruginosa
- coronavirus disease
- lung function
- respiratory syndrome coronavirus
- spinal cord
- biofilm formation
- chronic obstructive pulmonary disease
- systematic review
- mycobacterium tuberculosis
- high grade
- escherichia coli
- fine needle aspiration
- multidrug resistant
- air pollution
- drug resistant
- allergic rhinitis